Pet Care

Innovative peptide-based products for companion animal health and infection prevention

Protecting Our Pets

Companion animals face many of the same antimicrobial resistance challenges as humans. Overuse of conventional antibiotics in veterinary medicine has led to resistant infections that are increasingly difficult to treat.

Amphoraxe is developing peptide-based solutions specifically formulated for companion animal health, offering effective treatment options that reduce the risk of resistance development while keeping our pets healthy.

Pet care

Peptide Potency — Canine Ear Pathogens

Our top-performing peptides against each of the three primary canine ear infection pathogens.

S. aureus

Gram +
Peptide
FL24j4e
FL24a36
FL24n4e
FL24n7u
GL17z5g
GL21c4e
GL21z31
GL21t3p
FF24d6d
FF18z2w

Antibiotic Resistance Rates

95.6% fluoroquinolone-resistant 5

P. aeruginosa

Gram −
Peptide
WR29e11k
SW30l8v
KI23w67
IP20n6c
FM16e6t
RR17d6y
GL21z31
GL21t3p
GL21e44
GL21i3a

Antibiotic Resistance Rates

33% Marbofloxacin 9
43% Gentamicin 3
52% Enrofloxacin 3
82% Orbifloxacin 9

E. faecalis

Gram +
Peptide
GL21c4e
GL21z31
GL21t3p
IV14p4c
GL21o40
FL24a36
GK24x6k
PL24o31
GL21i3a
GL21m3z

Antibiotic Resistance Rates

24% Multidrug-resistant 6

Why Antimicrobial Peptides?

Unlike conventional antibiotics that target specific molecular pathways, antimicrobial peptides disrupt bacterial membranes through physical interaction. This fundamental difference in mechanism is central to our research focus:

Low Toxicity

HC50 & CC50 values 30–70× above MIC in our experiments — wide safety margin for host cells

Low Resistance

Membrane-targeting mechanism makes resistance evolution fundamentally difficult

Broad Spectrum

Active against Gram-positive and Gram-negative pathogens — multiple candidates show cross-pathogen activity

Synergy

Multi-peptide formulations enable broad-spectrum coverage

Bars represent relative potency (1/MIC) normalized to the most potent peptide per pathogen. MIC values are minimum inhibitory concentration (µg/mL) across all experiments conducted. E. faecalis is intrinsically resistant to cephalosporins, clindamycin, and aminoglycosides (as monotherapy) 7 — common vet antibiotics have no clinical activity against this pathogen.

Sources: 3 Mekic S et al. (2011). Vet Rec 169(5):125. PMID: 21742683 · 5 Azzariti S et al. (2022). Antibiotics 11(9):1204. PMC: 9494949 · 6 Kwon J et al. (2022). Vet Sci 9(11):592. PMC: 9695832 · 7 Hollenbeck BL, Rice LB (2012). Virulence 3(5):421-569. PMID: 23076243 · 9 KuKanich KS et al. (2022). J Vet Pharmacol Ther 45(5):454-462. PMID: 35698441

Partner With Us

Interested in co-developing antimicrobial peptides for companion animal health?

Get in Touch